Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899802 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
A Phase 2 study of Encephalitis, sponsored by Bavarian Nordic.
- Active
- Registry status
- Phase 2
- Development phase
- 411
- Enrollment target
- 9
- Study locations
NCT06899802 is a Phase 2 study of Encephalitis that is active but no longer recruiting, run by Bavarian Nordic. The registered enrollment target is 411 participants, below the 690-participant average among 4 other Encephalitis trials with a reported enrollment target (40% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT06899802, a Phase 2 study of Encephalitis, is active but no longer recruiting, sponsored by Bavarian Nordic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 411 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by VEEV and EEEV, in persons aged 18 years and older at high risk of exposure.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL MVA-BN-WEV
Study Locations (9)
Missouri
- Jefferson City Medical Group / Avacare - Jefferson City
- Clay-Platte Family Medicine, P.C./CCT Research - Kansas City
California
- Benchmark Research - Sacramento
Georgia
- Lifeline Primary Care, Inc. / CCT Research - Lilburn
Kansas
- Johnson County Clin-Trials - Lenexa
Kentucky
- Versailles Family Medicine, PLLC/CCT Research - Versailles
Louisiana
- Benchmark Research - Kenner
Nebraska
- Papillion Research Center/CCT Research - Papillion
Texas
- Benchmark Research - San Angelo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06899802
The ClinicalTrials.gov registry entry for NCT06899802 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 690-participant average among 4 other Encephalitis trials with a reported enrollment target (40% lower). The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Encephalitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06899802 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Missouri, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06899802 about?
NCT06899802 is a clinical study titled "A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine". This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by V...
What is the current status of trial NCT06899802?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 411 participants. The study started on 2025-03-10. Estimated completion is 2027-03.
What conditions does trial NCT06899802 study?
This clinical trial studies the following conditions: Encephalitis.
What interventions are being tested in trial NCT06899802?
The interventions under investigation include: Placebo (OTHER), MVA-BN-WEV (BIOLOGICAL).
Who is sponsoring clinical trial NCT06899802?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899802 being conducted?
This trial has 9 study locations across California, Georgia, Kansas, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Encephalitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.